The Regulatory Pathway to Biosimilar Approval

Join us for the third episode of the GHAPP & RhAPP Biosimilar Podcast Series, where host Amanda Mixon, PA-C, engages in an insightful conversation with Danielle Gatti-Palumbo, PharmD, BCACP, AAHIVP, about the Regulatory Pathway to Biosimilar Approval. As biosimilars continue to shape the future of rheumatology and gastroenterology, understanding their approval process is crucial for advanced practice providers (APPs) navigating this evolving treatment landscape.In this episode, we explore the totality of evidence approach, a rigorous evaluation process used by the FDA to determine biosimilarity. The discussion breaks down analytical testing for structural and functional characterization, nonclinical safety assessments, and comparative human pharmacokinetic (PK) and pharmacodynamic (PD) studies—all key components that ensure biosimilars match the safety and efficacy of their reference biologics. Additionally, immunogenicity assessments and comparative clinical studies are examined, offering valuable insight into how biosimilars gain regulatory approval.Biosimilars provide an opportunity to expand patient access to biologic therapies while addressing cost concerns in the healthcare system. However, insurance-driven switches and provider hesitancy require APPs to be well-versed in the regulatory pathway and confident in their ability to educate patients. This conversation highlights how biosimilars are evaluated at every stage—from structural integrity to real-world efficacy—ensuring no clinically meaningful differences exist compared to reference products.With biosimilars becoming more common, particularly in subcutaneous therapies, understanding their approval process is more important than ever. Whether you’re a rheumatology or gastroenterology provider, a clinical pharmacist, or a healthcare professional seeking clarity on biosimilars, this episode offers the expertise needed to navigate the future of biologic treatment options.Stay informed and enhance your clinical knowledge—subscribe to RhAPPcast on your favorite podcast platform and download the RhAPP ACE App for access to expert-driven resources, clinical updates, and continuing education in biosimilars and advanced rheumatology practice.Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval